Epidemiology Surveillance Program
Lebanese Ministry of Public Health
as on 23/08/2017
| Primary site | ASR | Crude rate | ICD (10th) | ||||
|---|---|---|---|---|---|---|---|
| ASR | ASR inf | ASR sup | Crude Rate | CR inf | CR sup | ||
| Lip | 0.12 | 0.02 | 0.21 | 0.1 | 0.0 | 0.2 | C00 |
| Tongue | 0.69 | 0.45 | 0.94 | 0.6 | 0.4 | 0.7 | C01-C02 |
| Mouth | 0.69 | 0.45 | 0.93 | 0.6 | 0.4 | 0.8 | C03-C06 |
| Salivary glands | 0.71 | 0.47 | 0.96 | 0.6 | 0.4 | 0.8 | C07-C08 |
| Tonsil | 0.12 | 0.02 | 0.22 | 0.1 | 0.0 | 0.2 | C09 |
| Other oropharynx | 0.05 | -0.05 | 0.15 | 0.0 | -0.0 | 0.1 | C10 |
| Nasopharynx | 0.63 | 0.38 | 0.87 | 0.5 | 0.3 | 0.7 | C11 |
| Hypopharynx | 0.04 | 0.04 | 0.04 | 0.0 | -0.0 | 0.1 | C12-C13 |
| Pharynx unsp. | 0.07 | -0.03 | 0.16 | 0.1 | -0.0 | 0.1 | C14 |
| Oesophagus | 0.90 | 0.62 | 1.18 | 0.7 | 0.5 | 0.9 | C15 |
| Stomach | 6.76 | 6.02 | 7.51 | 5.6 | 5.0 | 6.2 | C16 |
| Small intestine | 0.93 | 0.65 | 1.21 | 0.8 | 0.5 | 1.0 | C17 |
| Colon | 16.25 | 15.10 | 17.41 | 13.4 | 12.5 | 14.4 | C18 |
| Rectum | 6.63 | 5.88 | 7.38 | 5.4 | 4.8 | 6.0 | C19-C20 |
| Anus | 0.34 | 0.17 | 0.50 | 0.3 | 0.1 | 0.4 | C21 |
| Liver | 3.63 | 3.08 | 4.19 | 3.0 | 2.5 | 3.4 | C22 |
| Gallbladder etc. | 2.00 | 1.60 | 2.41 | 1.7 | 1.3 | 2.0 | C23-C24 |
| Pancreas | 4.63 | 4.01 | 5.26 | 3.7 | 3.2 | 4.2 | C25 |
| Nose & sinuses & etc. | 0.53 | 0.33 | 0.73 | 0.4 | 0.3 | 0.6 | C30-C31 |
| Larynx | 3.71 | 3.14 | 4.29 | 2.9 | 2.5 | 3.3 | C32 |
| Trachea bronchus & lung | 26.19 | 24.69 | 27.69 | 20.9 | 19.7 | 22.0 | C33-C34 |
| Other thoracic organs | 0.61 | 0.40 | 0.83 | 0.5 | 0.3 | 0.7 | C37-C38 |
| Bone | 1.37 | 1.06 | 1.68 | 1.3 | 1.0 | 1.6 | C40-C41 |
| Melanoma of skin | 1.52 | 1.17 | 1.87 | 1.3 | 1.0 | 1.6 | C43 |
| Other skin | 17.84 | 16.65 | 19.04 | 15.3 | 14.3 | 16.3 | C44 |
| Mesothelioma | 0.62 | 0.38 | 0.86 | 0.5 | 0.3 | 0.6 | C45 |
| Kaposi sarcoma | 0.24 | 0.11 | 0.38 | 0.2 | 0.1 | 0.3 | C46 |
| Connective & soft tissue | 3.63 | 3.08 | 4.17 | 3.1 | 2.6 | 3.5 | C47;C49 |
| Breast | 53.41 | 51.30 | 55.52 | 43.5 | 41.8 | 45.2 | C50 |
| Penis | 0.21 | 0.08 | 0.35 | 0.2 | 0.1 | 0.3 | C60 |
| Prostate | 18.79 | 17.54 | 20.04 | 15.7 | 14.7 | 16.7 | C61 |
| Testis | 1.67 | 1.33 | 2.01 | 1.7 | 1.4 | 2.0 | C62 |
| Other male genital | 0.01 | 0.01 | 0.01 | 0.0 | -0.0 | 0.1 | C63 |
| Kidney | 5.31 | 4.64 | 5.98 | 4.3 | 3.8 | 4.8 | C64 |
| Renal pelvis | 0.58 | 0.37 | 0.80 | 0.5 | 0.3 | 0.7 | C65 |
| Ureter | 0.12 | 0.02 | 0.21 | 0.1 | 0.0 | 0.2 | C66 |
| Bladder | 15.92 | 14.76 | 17.08 | 12.9 | 12.0 | 13.8 | C67 |
| Other urinary organs | 0.47 | 0.27 | 0.66 | 0.4 | 0.2 | 0.5 | C68 |
| Eye | 0.29 | 0.16 | 0.43 | 0.3 | 0.1 | 0.4 | C69 |
| Brain & nervous system | 5.69 | 5.01 | 6.37 | 4.9 | 4.3 | 5.5 | C70-C72 |
| Thyroid | 8.11 | 7.30 | 8.91 | 7.1 | 6.5 | 7.8 | C73 |
| Adrenal gland | 0.42 | 0.25 | 0.59 | 0.4 | 0.2 | 0.5 | C74 |
| Other endocrine | 0.10 | 0.01 | 0.20 | 0.1 | 0.0 | 0.2 | C75 |
| Hodgkin disease | 3.54 | 3.05 | 4.04 | 3.6 | 3.2 | 4.1 | C81 |
| Non-Hodgkin lymphoma | 13.97 | 12.91 | 15.03 | 11.9 | 11.0 | 12.8 | C82-C85;C96 |
| Immunoproliferative dis. | 0.03 | 0.03 | 0.03 | 0.0 | -0.0 | 0.1 | C88 |
| Multiple myeloma | 3.77 | 3.21 | 4.34 | 3.0 | 2.6 | 3.5 | C90 |
| Lymphoid leukemia | 4.29 | 3.71 | 4.86 | 3.8 | 3.3 | 4.3 | C91 |
| Myeloid leukemia | 3.21 | 2.70 | 3.72 | 2.8 | 2.3 | 3.2 | C92-C94 |
| Leukemia unsp. | 1.13 | 0.84 | 1.42 | 1.0 | 0.8 | 1.3 | C95 |
| Other & Unspecified | 12.23 | 11.23 | 13.24 | 10.0 | 9.2 | 10.8 | OTHER |
| All sites, total | 269.1 | 264.4 | 273.8 | 223.5 | 219.7 | 227.3 | All |
| All sites but C44 | 251.3 | 246.6 | 256.0 | 208.2 | 204.5 | 211.9 | Not C44 |
| * C44 refers to non melanoma skin cancer ASR: Age standardized rate using world standard population |
|||||||
|
LNCR Application Epidemiology Surveillance Program Lebanese Ministry of Public Health |
|